Used as a key intermediate in the synthesis of proteasome inhibitors, particularly in pharmaceuticals targeting cancer, such as bortezomib. Its boronic acid group enables reversible binding to threonine proteases, making it valuable in designing targeted therapies for multiple myeloma and other malignancies. Also employed in the development of biosensors and boron-containing compounds for neutron capture therapy.